SynthesisProstate cancer and prostatic diseases2026
Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies.
Synthesis in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transition from Oncologist- to Therapist-Led MRI-Guided Ultra-Hypofractionated Adaptive Prostate Radiation Therapy: Evaluation of Early Clinical Outcomes.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe technical advances allowed to take the leap towards hypofractionated schedules, as well as dose-escalated schedules, for prostate cancer (PCa) radiotherapy (RT). The aim of this systematic review is to describe RT techniques and toxicity outcomes within trials investigating hypofractionation, and to discuss current or future strategies to mitigate treatment-related toxicity.
methodsWe searched Pubmed database until June, 2025. Studies deemed eligible were phase III trials randomizing different type of fractionation (with at least one arm using hypofractionation) for PCa RT.
resultsThirty-two articles were included. Rates of late grade≥2 genitourinary (GU) toxicity ranged between 12-46% and 15-45% for patients receiving isodose and dose-escalated moderately hypofractionated radiotherapy (MHRT). A flare of grade≥2 GU toxicity was observed 12 to 24 months following stereotactic body radiotherapy (SBRT), translating into a higher cumulative incidence of grade≥2 GU toxicity at 5 years. Higher IPSS at baseline was suggested to be predictive of late grade≥2 GU toxicity following both MHRT and SBRT. Overall, MHRT does not seem to negatively impact late gastrointestinal (GI) toxicity, with rates of late grade≥2 toxicity ranging between 8.9-25% and 12.7-23.8% for isodose and dose-escalated MHRT. Current mitigation strategies include minimizing the dose delivered to organs at risk (OARs), prolonging overall treatment time, and personalizing treatments based on individual radiosensitivity. Among the strategies allowing for a reduction of the dose to adjacent OARs, margin reduction achieved through motion management strategies halved the rates of grade≥2 toxicity following PCa SBRT.
conclusionsGrade≥2 GU toxicity remains frequent in trials testing hypofractionation. Mitigation strategies are therefore critical to the continued evolution of intensified RT regimens. Motion management and margin reduction are particularly promising approaches to reduce severe toxicity after PCa SBRT, warranting their incorporation into clinical practice and future clinical trial designs.
Indexed as
Identifiers
41437135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.